Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRIUS-LN Extension Study of Ianalumab in Lupus Nephritis
NCT06711887Phase 3Recruiting
- Sponsor
- Novartis
- Start
- May 2025
- Primary completion
- Aug 2035
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, open-label trial of ianalumab in lupus nephritis (LN) (2 cohorts), sponsored by Novartis. Primary endpoints: Time to renal flare, increase in immunosuppressive medication, or death and Incidence and severity of adverse events (AEs) and serious adverse events (SAEs). Started May 2025; status: recruiting.
02
Drugs
ianalumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06711887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06711887.